Synergistic protection of Schizandrin B and Glycyrrhizic acid against bleomycin-induced pulmonary fibrosis by inhibiting TGF-β1/Smad2 pathways and overexpression of NOX4.

Autor: Zhang D; Department of Otorhinolaryngology Head and Neck Surgery, Institute of Otorhinolaryngology, Tianjin First Center Hospital, Tianjin 300192, China., Liu B; Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Logistic University of Chinese People's Armed Police Force, Tianjin 300162, China., Cao B; Department of Rescue Equipment Science, Logistics University of Chinese People's Armed Police Force, Tianjin 300162, China; Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Tianjin 300162, China. Electronic address: caobo19814@126.com., Wei F; Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Logistic University of Chinese People's Armed Police Force, Tianjin 300162, China., Yu X; Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Logistic University of Chinese People's Armed Police Force, Tianjin 300162, China., Li GF; Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Logistic University of Chinese People's Armed Police Force, Tianjin 300162, China., Chen H; Department of Rescue Equipment Science, Logistics University of Chinese People's Armed Police Force, Tianjin 300162, China., Wei LQ; Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Logistic University of Chinese People's Armed Police Force, Tianjin 300162, China., Wang PL; Clinic of Outpatient Department, Chinese People's Liberation Army General Hospital, Beijing 100853, China. Electronic address: Wangpeilan301@163.com.
Jazyk: angličtina
Zdroj: International immunopharmacology [Int Immunopharmacol] 2017 Jul; Vol. 48, pp. 67-75. Date of Electronic Publication: 2017 May 03.
DOI: 10.1016/j.intimp.2017.04.024
Abstrakt: Pulmonary fibrosis, a progressive and lethal lung disease, is a major therapeutic challenge for which new therapeutic strategies are warranted. Schisandrin B (Sch B) and Glycyrrhizic acid (GA) are the principal active ingredients of Schisandra chinensis and Glycyrrhiza glabra respectively, which have been reported to protect against lung injures. The present study was aimed at exploring the combinatorial therapeutic effects on bleomycin-induced pulmonary fibrosis. Lung fibrotic injuries were induced in mice by a single intratracheal instillation of 5mg/kg bleomycin (BLM). Then, these mice were administered with Sch B (100mg/kg) or/and GA (75mg/kg) for 28days. BLM-triggered structure distortion, collagen overproduction, excessive inflammatory infiltration, pro-inflammatory cytokine release, and oxidative stress damages in lung tissues were attenuated to a higher degree by combinatorial treatment than by treatment of the individual agents. The expression of TGF-β1 and the phosphorylation of its downstream target, Smad2 were enhanced by BLM, but weakened by Sch B or/and GA. Furthermore, the significant overexpression of NADPH oxidase 4 (NOX4) was observed in BLM-induced pulmonary fibrosis, which was inhibited by Sch B or/and GA. Our study reveals that the synergistic protection by Sch B and GA against BLM-induced pulmonary fibrosis is correlated to its anti-inflammatory, anti-oxidative and anti-fibrotic properties, involving inhibition of TGF-β1/Smad2 signaling pathways and overexpression of NOX4.
(Copyright © 2017 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: